News

Positive Long-term Outcomes with HeartFlow FFRCT and Plaque Analysis Demonstrated in ADVANCE-DK Registry at TCT 2024

Data confirm the use of FFRCT and Plaque Analysis helps assess long-term risks, informing more personalized and effective treatment plans…

1 month ago

Biogen Presents Positive Results from Phase 2 IGNAZ Study of Felzartamab in IgA Nephropathy at American Society of Nephrology (ASN) Kidney Week 2024

The detailed study results confirmed interim findings, showing stable kidney function and sustained treatment effect more than 18 months after…

1 month ago

Novartis oral Fabhalta® (iptacopan) sustained clinically meaningful results at one year in Phase III C3 glomerulopathy (C3G) trial 

New APPEAR-C3G data show Fabhalta sustained proteinuria reduction at 12 months1Upon Fabhalta initiation, improvement observed in estimated glomerular filtration rate…

1 month ago

Vera Therapeutics Announces 96-week eGFR Stabilization in ORIGIN Phase 2b Study of Atacicept in IgAN in a Late-Breaking Oral Presentation at the American Society of Nephrology Kidney Week 2024

Long-term improvements observed in the quartet of findings defining disease modification supports atacicept’s potential to prevent kidney failure in patients…

1 month ago

Celldex Announces Barzolvolimab Met All Primary and Secondary Endpoints with High Statistical Significance in Positive Phase 2 Study in Chronic Inducible Urticaria

First to demonstrate clinical benefit in patients with chronic inducible urticaria (CIndU) in large, randomized, placebo-controlled study Favorable safety and tolerability…

1 month ago

Pivotal VALIANT Results Presented at Kidney Week Highlight Strength of Pegcetacoplan Treatment Effect in Patients with C3G / Primary IC-MPGN

Statistically significant 68% (p<0.0001) proteinuria reduction compared to placebo, with reduction observed as early as Week 4 All secondary endpoints…

1 month ago

B&D Capital Partners Advises MedShift

CHARLOTTE, N.C.--(BUSINESS WIRE)--B&D Capital Partners is pleased to announce the successful placement of an $89.5 million debt financing led by…

1 month ago

Oral Health Basics: What Mobile Residents Should Know

NEW YORK, NY / ACCESSWIRE / October 26, 2024 / Along with helping you eat and speak, strong teeth also…

1 month ago

Travere Therapeutics Presents Data Reinforcing Clinical Benefit of FILSPARI® (Sparsentan) in IgAN and Late-Breaking Presentation in FSGS at ASN Kidney Week 2024

Nearly 60% of patients with IgAN in the SPARTAN Study achieved complete remission when using FILSPARI as first-line treatment SPARTACUS…

1 month ago

Vivoryon Therapeutics N.V. Presents Outstanding Phase 2b Results of Varoglutamstat on Kidney Function at ASN Kidney Week 2024

Vivoryon Therapeutics N.V. Presents Outstanding Phase 2b Results of Varoglutamstat on Kidney Function at ASN Kidney Week 2024 Selected for…

1 month ago